Skip to main content

Table 2 Treatment emergent AEs reported in >5% of subjects (3 or more), excluding mild and not related to treatment

From: Tetrabenazine as anti-chorea therapy in Huntington Disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators

Adverse Event

# of Subjects

Sedation/Somnolence

18

Depressed Mood

17

Anxiety

13

Insomnia

10

Akathisia

9

Fatigue

7

Agitation

5

Fall

4

Dysphagia

3

Dystonia

3